blinatumomab
Blinatumomab Increases Disease-Free Survival for Children With Leukemia
Children with B-acute lymphoblastic leukemia who received blinatumomab plus standard chemotherapy were 61% less ...
DECEMBER 11, 2024
FDA Expands Approval of Blincyto for Certain ALL Patients at Risk for Relapse
Blincyto is the first and only FDA-approved therapy for minimal residual ALL.
MARCH 29, 2018
FDA Grants New Pediatric Indication for Blincyto
Blinatumomab met its primary Phase II endpoint in 93 children with ALL of complete remission within the first two ...
OCTOBER 14, 2016
Load more